This article shares key insights from MD&M West 2026 in Anaheim, one of the largest industry events in medical devices and manufacturing. It explores how regulatory expectations, innovation, and real-world industry dynamics are evolving — and what this means for professionals working at the intersection of MedTech, quality, and regulatory affairs.

This article builds on key discussions from a recent biostatistics and biopharma innovation symposium, exploring how science, data, and capital are reshaping the industry. It highlights the major forces defining biopharma in 2025 — including innovation trends, funding dynamics, regulatory shifts, and the growing competition between the U.S. and China.